Adverse event reporting information can be found at the bottom of the page

INTRODUCING WOCKAIR®

(budesonide/formoterol fumarate dihydrate, inhalation powder)

Choose WockAIR® 160/4.5mcg as your preferred controller and reliever for your patients with asthma aged 12 years and over at all treatment steps1.

  • Budesonide/formoterol reduces the risk of asthma exacerbations compared to SABA containing regimens1-4
  • It is simple – your patients will only need one inhaler for AIR or MART 1,5
  • ICS/formoterol anti-inflammatory reliever is recommended by GINA and it replaces SABA5
  • NICE recommends licensed low dose ICS/formoterol combination inhaler therapy for AIR and MART(6)
  • It is bioequivalent to the originator Symbicort Turbohaler

    (based on 80-125% bioequivalence limits for AUC, Cmax, and standard flow parameters) 7

  • The WockAIR® device is patient friendly with a lower carbon footprint than pMDIs (in line with NHS carbon reduction strategy)8,9
Learn more
WockAir
WockAIR Icon

ASTHMA

Find out more about asthma treatment with WockAIR®

Learn more

COPD

Find out more about COPD treatment with WockAIR®

Learn more

Adverse events should be reported. Reporting forms and information can be found at: https://yellowcard.mhra.gov.uk/

Adverse events should also be reported to Wockhardt UK. Please contact us or email us at drug.safety@wockhardt.co.uk

References

1. WockAIR® Summary of Product Characteristics

2. Sobieraj DM, Weeda ER, Nguyen E, et al. Association of inhaled corticosteroids and long-acting β-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis. JAMA 2018; 319: 1485–1496

3. Beasley R, DSc; Harrison T, Peterson S et al. Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients With Poorly Controlled Asthma: A Systematic Review and Meta-analysis. JAMA Network Open. 2022;5(3):e220615. doi:10.1001/jamanetworkopen.2022.0615

4. Crossingham I et al. Cochrane Database Syst Rev 2021; 5(5): CD013518

5. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2023. Updated July 2023. Available from www.ginasthma.org

6. NICE Guideline: Asthma: Diagnosis, monitoring and chronic asthma management 27 Nov 2024 Available at www.nice.org/guidance/ng245

7. Wockhardt Data on File

8. Janson C, et al. Thorax 2020;75:82–84. doi:10.1136/thoraxjnl-2019-213744. Carbon footprint impact of the choice of inhalers for asthma and COPD

9. Virchow JC, Weuthen T, Harmer QJ, Jones S. Identifying the features of an easy-to-use and intuitive dry powder inhaler for asthma and chronic obstructive pulmonary disease therapy: results from a 28-day device handling study, and an airflow resistance study. Expert Opin Drug Deliv. 2014;11(12):1849–57

10. MIMS May 2025

ABBREVIATIONS

AIR-anti-inflammatory reliever; MART – Maintenance and Reliever Therapy; COPD- Chronic Obstructive Pulmonary Disease; pMDI- pressurised metered dose inhaler; AUC- area under curve; SABA- short acting beta agonist

This site is intended for UK Healthcare Professionals.
Contact Us | Cookies and Privacy Policy | Terms of and Conditions of Use | Sitemap | PIL | Pharmacovigilance Privacy Notice
Job code: AIR06/25 July 2025